Literature DB >> 22230586

A genomics-based approach to assessment of vaccine safety and immunogenicity in children.

Olivia J White1, Katherine L McKenna, Anthony Bosco, Anita H J van den Biggelaar, Peter Richmond, Patrick G Holt.   

Abstract

Immune responses to vaccines in infants and young children are typically Th2-biased, giving rise to concerns regarding potential atopy-like side effects, and antagonism of Th1-associated sterilising immunity. Conventional immunological methodology has limited capacity to effectively address these problems because of the inherent complexity of the immune responses involved. In the present study, we sought to develop an unbiased systems biology approach to elucidate superficially similar Th2-associated responses to paediatric vaccines and allergens, and to differentiate between them via gene coexpression network analysis. We demonstrate below that in immune responses to the diptheria/acellular pertussis/tetanus and pneumococcal polysaccharide conjugate vaccines, potentially antagonistic Th1-/IFN-associated and Th2-associated gene networks coexist in an apparent state of dynamic equilibrium, whereas in Th2-dominant allergen-specific responses of atopics the Th1 and IFN networks are respectively disrupted and downregulated. Capacity to detect and interpret these covert differences between responses to vaccines and allergens relies on the use of sophisticated algorithms that underpin coexpression network analysis, which identify genes that function co-ordinately in complex pathways. This methodology has significant potential to identify covert interactions between inflammatory pathways triggered by vaccination, and as such may be a useful tool in prediction of vaccine safety/efficacy. Copyright Â
© 2011 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22230586     DOI: 10.1016/j.vaccine.2011.12.118

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  9 in total

Review 1.  Recent progress in mucosal vaccine development: potential and limitations.

Authors:  Nils Lycke
Journal:  Nat Rev Immunol       Date:  2012-07-25       Impact factor: 53.106

Review 2.  Enhancing vaccine safety capacity globally: A lifecycle perspective.

Authors:  Robert T Chen; Tom T Shimabukuro; David B Martin; Patrick L F Zuber; Daniel M Weibel; Miriam Sturkenboom
Journal:  Vaccine       Date:  2015-10-01       Impact factor: 3.641

3.  Loss of multi-epitope specificity in memory CD4(+) T cell responses to B. pertussis with age.

Authors:  Wanda G H Han; Inonge van Twillert; Martien C M Poelen; Kina Helm; Jan van de Kassteele; Theo J M Verheij; Florens G A Versteegh; Claire J P Boog; Cécile A C M van Els
Journal:  PLoS One       Date:  2013-12-31       Impact factor: 3.240

Review 4.  Hib Vaccines: Past, Present, and Future Perspectives.

Authors:  Adi Essam Zarei; Hussein A Almehdar; Elrashdy M Redwan
Journal:  J Immunol Res       Date:  2016-01-20       Impact factor: 4.818

5.  A Novel Structure of Blockchain Applied in Vaccine Quality Control: Double-Chain Structured Blockchain System for Vaccine Anticounterfeiting and Traceability.

Authors:  Zehuan Qiu; Yifan Zhu
Journal:  J Healthc Eng       Date:  2021-03-19       Impact factor: 2.682

Review 6.  Vaccine-Induced Cellular Immunity against Bordetella pertussis: Harnessing Lessons from Animal and Human Studies to Improve Design and Testing of Novel Pertussis Vaccines.

Authors:  Anja Saso; Beate Kampmann; Sophie Roetynck
Journal:  Vaccines (Basel)       Date:  2021-08-07

Review 7.  Comparative Safety of Vaccine Adjuvants: A Summary of Current Evidence and Future Needs.

Authors:  Nikolai Petrovsky
Journal:  Drug Saf       Date:  2015-11       Impact factor: 5.606

8.  Transcriptome signature for dampened Th2 dominance in acellular pertussis vaccine-induced CD4(+) T cell responses through TLR4 ligation.

Authors:  Jolanda Brummelman; René H M Raeven; Kina Helm; Jeroen L A Pennings; Bernard Metz; Willem van Eden; Cécile A C M van Els; Wanda G H Han
Journal:  Sci Rep       Date:  2016-04-27       Impact factor: 4.379

9.  Comprehensive assessment of serious adverse events following immunization by health care providers.

Authors:  S Elizabeth Williams; Kathryn M Edwards; Roger P Baxter; Philip S LaRussa; Neal A Halsey; Cornelia L Dekker; Claudia Vellozzi; Colin D Marchant; Peter D Donofrio; Tyler E Reimschisel; Melvin Berger; Jane F Gidudu; Nicola P Klein
Journal:  J Pediatr       Date:  2013-02-26       Impact factor: 4.406

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.